Teva Pharmaceutical shares surge 85% on branded pivot and pipeline optimism
Analysts point to duvakitug’s phase 3 potential and a valuation under 10 times 2027 earnings as key drivers for the pharmaceutical giant’s continued recovery.
Teva Pharmaceutical Industries has seen its shares climb approximately 85% over the past 12 months, marking a significant milestone in its strategic transition from a generic-focused manufacturer to a branded pharmaceutical leader. The shift is now structurally evident in the company’s financials, with first-quarter 2026 data indicating that generic drugs no longer constitute the majority of overall sales. This milestone underscores the success of Teva’s pivot, which has been supported by mid-double-digit annual sales growth in branded products such as Austedo, Ajovy, and Uzedy.
Despite the strong share price performance, management forecasts a near-term dip in earnings per share, projecting a decline from $2.65 in 2025 to a range of $1.91 to $2.11 in 2026. This contraction is primarily attributed to the dilutive impact of the recent acquisition of Emalex Biosciences. However, the company anticipates that operating profit and adjusted EBITDA will increase by 30% starting in 2027, driven by the anticipated launch of biosimilars and continued growth in its flagship branded drugs.
A central focus for investors is duvakitug, a treatment for ulcerative colitis and Crohn’s disease co-developed with Sanofi. The drug is currently in phase 3 clinical trials, following promising results in phase 2b. If the phase 3 outcomes mirror these earlier findings, management estimates that duvakitug could achieve peak annual sales between $2 billion and $5 billion, positioning it as a potential blockbuster that could further accelerate the company’s turnaround.
Market valuation metrics suggest the stock remains attractive relative to its future earnings potential. Teva shares are currently trading at less than 10 times estimated 2027 earnings, a multiple that some analysts view as a discount given the pipeline’s growth prospects. The combination of a shrinking generic footprint, rising branded revenue, and a high-value late-stage asset has kept the stock in focus for long-term investors seeking exposure to the pharmaceutical sector’s evolving landscape.
The company’s trajectory highlights the risks and rewards inherent in pharmaceutical turnarounds. While the Emalex acquisition has temporarily weighed on per-share metrics, the structural shift toward higher-margin branded and biosimilar products is expected to bolster profitability in the medium term. As duvakitug progresses through its final clinical stages, it stands as the primary catalyst for the next phase of growth, potentially validating the market’s confidence in Teva’s new strategic direction.
